Research programme: immuno-oncology targeted antibodies - Checkpoint Therapeutics

Drug Profile

Research programme: immuno-oncology targeted antibodies - Checkpoint Therapeutics

Alternative Names: Anti-CAIX antibodies; Anti-GITR antibodies; CK 302

Latest Information Update: 02 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dana-Farber Cancer Institute
  • Developer Checkpoint Therapeutics; TG Therapeutics Inc
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Carbonic anhydrase inhibitors; TNFRSF18 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 28 Apr 2017 Checkpoint Therapeutics announces intention to submit an IND application for CK 301 for Cancer in 2017
  • 28 Apr 2017 Checkpoint Therapeutics announces intention to submit an IND application for the anti-GITR antibody CK 302 and anti-CAIX antibody for Cancer in 2018
  • 04 Apr 2017 TG Therapeutics plans a first-in-human phase I trial for CK 301 for Cancer (Second-line therapy or greater, Metastatic disease, Late-stage disease, Inoperable/ Unresectable) (IV) (NCT03212404)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top